EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2073-2078

  Planchard, David ^a   Loriot, Y ^a   Andre F ^a,b   Gobert, A ^a   Auger, N ^a   Lacroix, L ^a   Soria, J C ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Universite Paris Sud   (France)

Author keywords

AZD9291; EGFR; HER2; MET; NSCLC; T790M

Indexed keywords

ALANINE; ARGININE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GLUTAMIC ACID; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHIONINE; OSIMERTINIB; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SERINE; THREONINE; TRASTUZUMAB; ACRYLAMIDE DERIVATIVE; ANILINE DERIVATIVE; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MET PROTEIN, HUMAN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CANCER INHIBITION; CANCER PATIENT; CASE REPORT; CELL POPULATION; CENTROMERE; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG BINDING SITE; DRUG SUBSTITUTION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NODULE; MALE; MIDDLE AGED; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUROSURGERY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PLEURA METASTASIS; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT RESPONSE; TUMOR BIOPSY; WILD TYPE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROGNOSIS;

ACRYLAMIDES; ANILINE COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84943744661     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv319     Document Type: Article

References (20)

1. Barlesi F, Blons H, Beau-Faller M et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol ASCO 2013; 31(suppl); abstr 8000.
2. Kris MG, Johnson BE, Berry LD et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998-2006.
3. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
4. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
5. Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-151.
6. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
7. Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-2247.
8. Cross DA, Ashton SE, Ghiorghiu S et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-1061.
9. Janne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant nonsmall- cell lung cancer. N Engl J Med 2015; 372: 1689-1699.
10. Thress KS, Paweletz CP, Felip E et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21: 560-562.
11. Helena AY, Shaozhou KT, Alexander ED et al. Acquired resistance of EGFRmutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol 2015 May 7 [epub ahead of print], doi: 10.1001/jamaoncol.2015.1066.
12. Ferté C, Massard M, Ileana E et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. Can Res 2014; 74(Suppl 19): abstr CT240.
13. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043.
14. Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
15. Lutterbach B, Zeng Q, Davis LJ et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007; 67:2081-2088.
16. Takezawa K, Pirazzoli V, Arcila ME et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012; 2:922-933.
17. Piotrowska Z, Niederst MJ, Karlovich CA et al. Heterogeneity underlies the emergence of EGFR T790 wild-type clones following treatment of T790Mpositive cancers with a third generation EGFR inhibitor. Cancer Discov 2015; 5: 713-722.
18. Ercan D, Choi HG, Yun CH et al. EGFR mutations and resistance to irreversible pyrimidine based EGFR inhibitors. Clin Cancer Res 2015; 21(17): 3913-3923.
19. Tricker EM, Xu C, Uddin S et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR mutant lung cancer. Cancer Discov 2015; 5(9): 960-971.
20. Eberlein CA, Stetson D, Markovets AA et al. Acquired resistance to mutantselective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res 2015; 75: 2489-2500.